OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
World game at war: why some European nations have threatened a World Cup boycott 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
LAWRENCEVILLE, N.J., May 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held on May 8 – 9, 2018 at Reed Smith, LLP in New York City. Mr. Tardugno’s presentation details are as follows:
Corporate Presentation:
- Date and Time: Tuesday, May 8, 2017 at 9:30 a.m. – 9:50 a.m. EDT
- Location: Room A/B
Slide Presentation Available on Celsion’s Website
To view Mr. Tardugno’s slide presentation from the event, please visit Celsion’s corporate website at http://investor.celsion.com/financial-events .
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact Jeffrey W. Church Sr. Vice President and CFO 609-482-2455 [email protected]
